Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)
The summary for the Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional): The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.
Federal Grant Title: | Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-21-016 |
Type of Funding: | Grant |
CFDA Numbers: | 93.279 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | February 26th, 2021 |
Original Application Deadline: | February 26th, 2021 |
Posted Date: | December 23rd, 2020 |
Creation Date: | December 23rd, 2020 |
Archive Date: | April 3rd, 2021 |
Total Program Funding: | $2,000,000 |
Maximum Federal Grant Award: | $256,580 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | December 23rd, 2020 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-016.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Tr...
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Tr...
- • NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/U...
- • ML/AI Tools to Advance Genomic Translational Research (MAGen) - Coordinating Center (UG3/U...
- • Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01...